RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: This phase II trial is studying how well allogeneic stem cell transplant works in treating patients with metastatic kidney cancer.

开始日期2002-11-04

申办/合作机构

UNICANCER

100 项与 Allogeneic lymphocytes(UNICANCER) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic lymphocytes(UNICANCER) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic lymphocytes(UNICANCER) 相关的专利（医药）

登录后查看更多信息

项与 Allogeneic lymphocytes(UNICANCER) 相关的文献（医药）

2020-12-16·Journal of Bone and Joint Surgery2区 · 医学

Commentary on an article by Chris Hyunchul Jo, MD, et al.: “Allogeneic Platelet-Rich Plasma Versus Corticosteroid Injection for the Treatment of Rotator Cuff Disease. A Randomized Controlled Trial”

2区 · 医学

Article

作者: Werner, Brian C

2020-10-09·Medicinski Glasnik

Allogenic platelet concentrates from umbilical cord blood for knee osteoarthritis: preliminary results

Article

作者: Ippolito, Francesco ; Visceglie, Domenico ; Caiaffa, Vincenzo ; Santodirocco, Michele ; Abate, Antonella ; Nappi, Vittorio

Aim To investigate the role of cordonal blood platelet-rich plasma (PRP) intra-articular injections for treating the patients with knee osteoarthritis in terms of procedure safety and clinical outcomes. Methods Twenty-five patients affected by knee osteoarthritis were enrolled and received one single intra-articular knee injection of umbilical cord PRP in a volume of 10 mL. A follow-up was investigated at time 0, 4, 8, 12 weeks and 6 months, evaluating clinical parameters and functional performances. Results No serious adverse events were identified. The paired ttest analysis showed a significant difference between baseline and each follow-up times for all clinical scales (p&lt;0.05), with a significant improvement of clinical outcomes. Conclusion Allogeneic PRP can generate reliable therapeutic effect. The high content of tissue regenerative factors in cord blood platelets makes cordonal blood one of the ideal sources of PRP.&nbsp;

2013-01-01·Journal of Orthopaedic Surgery and Research3区 · 医学

Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis

3区 · 医学

ArticleOA

作者: Justin S Field ; Jeffrey S Roh ; R Trigg McClellan ; Christopher A Yeung

BACKGROUNDSince the introduction of rhBMP-2 (Infuse) in 2002, surgeons have had an alternative substitute to autograft and its related donor site morbidity. Recently, the prevalence of reported adverse events and complications related to the use of rhBMP-2 has raised many ethical and legal concerns for surgeons. Additionally, the cost and decreasing reimbursement landscape of rhBMP-2 use have required identification of a viable alternative. Osteo allogeneic morphogenetic protein (OsteoAMP) is a commercially available allograft-derived growth factor rich in osteoinductive, angiogenic, and mitogenic proteins. This study compares the radiographic fusion outcomes between rhBMP-2 and OsteoAMP allogeneic morphogenetic protein in lumbar interbody fusion spine procedures.METHODSThree hundred twenty-one (321) patients from three centers underwent a transforaminal lumbar interbody fusion (TLIF) or lateral lumbar interbody fusion (LLIF) procedure and were assessed by an independent radiologist for fusion and radiographically evident complications. The independent radiologist was blinded to the intervention, product, and surgeon information. Two hundred and twenty-six (226) patients received OsteoAMP with autologous local bone, while ninety-five (95) patients received Infuse with autologous local bone. Patients underwent radiographs (x-ray and/or CT) at standard postoperative follow-up intervals of approximately 1, 3, 6, 12, and 18 months. Fusion was defined as radiographic evidence of bridging across endplates, or bridging from endplates to interspace disc plugs. Osteobiologic surgical supply costs were also analyzed to ascertain cost differences between OsteoAMP and rhBMP-2.RESULTSOsteoAMP produced higher rates of fusion at 6, 12, and 18 months (p ≤ 0.01). The time required for OsteoAMP to achieve fusion was approximately 40% less than rhBMP-2 with approximately 70% fewer complications. Osteobiologic supply costs were 80.5% lower for OsteoAMP patients (73.7% lower per level) than for rhBMP-2.CONCLUSIONSResults of this study indicate that OsteoAMP is a viable alternative to rhBMP-2 both clinically and economically when used in TLIF and LLIF spine procedures.

100 项与 Allogeneic lymphocytes(UNICANCER) 相关的药物交易

登录后查看更多信息